|Day Low/High||8.65 / 9.01|
|52 Wk Low/High||8.37 / 39.49|
Esperion Therapeutics, Agenus Inc. and Baudax Bio could see coming events trigger positive reactions in their shares.
Merger activity is the number 1 driver I am watching for biotech growth.
Strong markets tend to stay sticky to the upside, and the mild pressure on the indices isn't preventing some good stock picking.
There is much talk that IBM is overpaying for Red Hat, but this deal is a net positive for the market as a whole.
Biotech companies show more energy than the rest of the market Monday.
I'm starting a new periodic feature that will bring you the hottest-trading stocks I see.
Not a big day of gains, but there is underlying support.
Wal-Mart sets the tone, but selling hasn't been bad enough to kill rally.
Only one fund category (of 20) has beaten the S&P 500 over half a decade.
Three biotech companies are going public this week and NanoString looks better than Prosensa or Esperion says Francis Gaskins.